UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of oncology, 2023-10, Vol.34, p.S325-S325

2023

Volltextzugriff (PDF)

66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S571

2022

Volltextzugriff (PDF)

731P Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study

Annals of oncology, 2021-09, Vol.32, p.S733-S734

2021

Volltextzugriff (PDF)

Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit

Annals of oncology, 2018-06, Vol.29, p.v18-v18

2018

Volltextzugriff (PDF)

1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Annals of oncology, 2019-10, Vol.30, p.v651-v652

2019

Volltextzugriff (PDF)

Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Annals of oncology, 2019-10, Vol.30, p.v651-v652

2019

Volltextzugriff (PDF)

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Annals of oncology, 2023-10, Vol.34, p.S426-S427

2023

Volltextzugriff (PDF)

Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies

Annals of oncology, 2016-10, Vol.27, p.vi196-vi196

2016

Volltextzugriff (PDF)

131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886

Annals of oncology, 2022-11, Vol.33, p.S1483-S1483

2022

Volltextzugriff (PDF)

1199P Identification of patient specific immune therapy treatment sensitivity by ex vivo testing

Annals of oncology, 2020-09, Vol.31, p.S788-S788

2020

Volltextzugriff (PDF)

Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry

Annals of oncology, 2016-10, Vol.27, p.vi160-vi160

2016

Volltextzugriff (PDF)

Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry

Annals of oncology, 2016-10, Vol.27, p.vi162-vi162

2016

Volltextzugriff (PDF)

CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Annals of oncology, 2016-10, Vol.27, p.vi132-vi132

2016

Volltextzugriff (PDF)

Bevacizumab first line and impact on subsequent anti-EGFR activity

Annals of oncology, 2017-09, Vol.28, p.v178-v178

2017

Volltextzugriff (PDF)

Does Exact Primary Site Impact on Outcome for Metastatic Colorectal Cancer (Mcrc)?

Annals of oncology, 2014-09, Vol.25, p.iv174

2014

Volltextzugriff (PDF)

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines super()

Annals of oncology, 2014-01, Vol.25 (1), p.117-121

2014

Volltextzugriff (PDF)

Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

Annals of oncology, 2012-09, Vol.23, p.ix493-ix494

2012

Volltextzugriff (PDF)

1525P - Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

Annals of oncology, 2012-09, Vol.23, p.ix493-ix494

2012

Volltextzugriff (PDF)

1582PEstimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

Annals of oncology, 2008, Vol.19 (6), p.1090-1096

2008

Volltextzugriff (PDF)

446PDPhase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

P-065Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit

Annals of oncology, 2018-06, Vol.29 (suppl_5)

2018

Volltextzugriff (PDF)

474PPharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

Annals of oncology, 2012-11, Vol.23 (11), p.2843

2012

Volltextzugriff (PDF)

514PDOES EXACT PRIMARY SITE IMPACT ON OUTCOME FOR METASTATIC COLORECTAL CANCER (MCRC)?

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv174-iv174

2014

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink_现刊

ThemaScience & Technology

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(29)
Russisch
(1)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(30)
Journals@Ovid
(30)
IngentaConnect
(5)
MEDLINE
(3)
Springer Nature - Complete Springer Journals
(0)

Menü

Weitere Dienste

Einstellungen

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

731P Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study

Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit

1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies

131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886

1199P Identification of patient specific immune therapy treatment sensitivity by ex vivo testing

Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry

Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry

CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Bevacizumab first line and impact on subsequent anti-EGFR activity

Does Exact Primary Site Impact on Outcome for Metastatic Colorectal Cancer (Mcrc)?

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines super()

Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

1525P - Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

1582PEstimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

446PDPhase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

P-065Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit

474PPharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

514PDOES EXACT PRIMARY SITE IMPACT ON OUTCOME FOR METASTATIC COLORECTAL CANCER (MCRC)?

Aktive Filter

Suchergebnisse filtern